1) Strong Financial Performance
- Full-year revenue for 2025 reached $65.2 billion, a 45% increase compared to 2024.
- Q4 revenue grew 43% YoY, driven by key products, with earnings per share rising 86% to $7.54.
- Gross margin remained stable at 83.2%, while R&D and marketing expenses increased by 26% and 29%, respectively.
- Non-GAAP performance margin improved to 47.2%, up 4.2 percentage points from Q4 2024.

2) Product and Pipeline Advancements
- Launched new medicines like Inlureo and expanded indications for Omvo and Jayperca.
- Significant clinical progress with 25 phase three trials and submissions for Orforglipron in obesity across the US and 40 countries.
- Strong performance from key products, with Mounjaro and Zepbound leading in their respective markets, achieving over 55% and 70% of new prescriptions in the US.
- Continued investment in AI for drug discovery and expansion of manufacturing capabilities, with a commitment of $55 billion since 2020.

3) Market Dynamics and Challenges
- Anticipated pricing pressures in 2026 due to government agreements and Medicaid changes, expected to impact revenue growth by low to mid-teens percentage.
- Competition in the incretin market is increasing, but Lilly expects Orforglipron to expand the overall market rather than cannibalize existing products.
- Some challenges in securing Medicaid coverage, particularly in states like California, which may reduce access temporarily.

4) Guidance and Future Outlook
- 2026 revenue guidance set between $80 billion and $83 billion, representing a 25% increase from 2025.
- Expected earnings per share between $33.50 and $35, indicating continued strong growth.
- Anticipated launch of Orforglipron in the US and most international markets by 2027, with a focus on expanding access and market penetration.
- Continued investment in R&D with 36 active Phase III programs and plans for new trials in various therapeutic areas.

5) Leadership and Strategic Focus
- Strengthened leadership team with new executives in key roles, enhancing strategic direction.
- Focus on expanding the incretin portfolio and exploring new therapeutic areas, including immunology and oncology.
- The call lacked detailed Q&A on specific product launch metrics and competitive positioning against emerging therapies.

Bottom line: Eli Lilly's strong financial performance in 2025, driven by innovative product launches and a robust pipeline, positions the company well for future growth despite anticipated pricing pressures and market competition. The strategic focus on expanding access to obesity treatments and leveraging AI in drug development further enhances its long-term outlook for shareholders.